UC San Diego

UC San Diego Previously Published Works

Title

Immune Escape of AML Cells after Transplantation.

Permalink

<https://escholarship.org/uc/item/7vv356xx>

Journal

The New England journal of medicine, 380(13)

ISSN

0028-4793

Authors

Goodman, Aaron M

Kurzrock, Razelle

Publication Date

2019-03-01

DOI

10.1056/nejmc1900424

Peer reviewed

Letter to the Editor Regarding “Immune Escape of Relapsed AML Cells after Allogeneic Transplantation”

Aaron M. Goodman MD¹ and Razelle Kurzrock MD¹

Affiliations: ¹University of California San Diego Moores Cancer Center, La Jolla, CA, USA.

To whom correspondence should be addressed: A.G. (a1goodman@ucsd.edu). UC San Diego Moores Cancer Center 3855 Health Sciences Drive. La Jolla, CA, 92093-0658. (847)-363-8139 (Direct). (858)-246-1915 (Fax)

COI: Aaron Goodman receives speaking fees from Seattle Genetics and consulting fees from Jazz Pharmaceuticals. Razelle Kurzrock receives research funding from Genentech, Incyte, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant, as well as consultant fees from Loxo, X Biotech, and Actuate Therapeutics, speaker fees from Roche, and an ownership interest in Curematch Inc.

175 words

Received within three week after publication

Christopher *et al.* compares 15 acute myeloid leukemia patients who relapsed after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) to 20 patients who relapsed after chemotherapy. All patients had exome sequencing on paired samples obtained at initial presentation and at relapse.¹ RNA sequencing was performed on a subgroup. The authors' note relapse after allo-HSCT is not associated with acquisition of unique mutations. However, RNA sequencing revealed dysregulation of immune pathways. One patient acquired *PDL1/PDL2* gene amplification after allo-HSCT. The authors conclude that this finding is not a common mechanism of immune escape in AML after transplantation. We would caution the authors' regarding their conclusion as this is a small sample size (15 patients). A prior study revealed no *PDL1/PDL2* amplifications amongst 1273 AMLs.² Further studies are needed to determine if *PDL1/PDL2* amplification is only seen in AML patients who relapse after allo-HSCT. Hodgkin lymphoma is exquisitely sensitive to PD1 blockade due to the near-universal presence of *PDL1/PDL2* amplification.³ Whether or not patients with AML who relapse after allo-HSCT and show *PDL1/PDL2* amplification respond to immunotherapy warrants investigation.

Works Cited

1. Christopher MJ, Petti AA, Rettig MP, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. *N Engl J Med* 2018;
2. Goodman AM, Piccioni D, Kato S, et al. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. *JAMA Oncol* 2018.
3. Roemer MGM, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. *J Clin Oncol* 2016;34(23):2690–7.